Euroapi Company Header Euroapi Company Header

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Kalbe Genexine Biologics","sponsor":"Genexine","pharmaFlowCategory":"D","amount":"$1,100.0 million","upfrontCash":"$27.0 million","newsHeadline":"KGBio and Genexine Signed Immuno-Oncology Drug License Agreement GX-17","therapeuticArea":"Oncology","highestDevelopmentStatus":"Phase I","country":"INDONESIA","productType":"Large molecule","productStatus":"New Molecular Entity","date":"February 2021","url1":"","url2":"","graph1":"Oncology","graph2":"Phase I"},{"orgOrder":0,"company":"Kalbe Genexine Biologics","sponsor":"Shanghai Henlius Biotech","pharmaFlowCategory":"D","amount":"$665.0 million","upfrontCash":"$7.0 million","newsHeadline":"Henlius Expands Collaboration with KGbio to Develop, Commercialize and Supply Henlius' novel anti-PD-1 mAb HANSIZHUANG in MENA","therapeuticArea":"Oncology","highestDevelopmentStatus":"Approved","country":"INDONESIA","productType":"Large molecule","productStatus":"Approved","date":"September 2023","url1":"","url2":"","graph1":"Oncology","graph2":"Approved"},{"orgOrder":0,"company":"Kalbe Genexine Biologics","sponsor":"Genexine","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Genexine and KGbio Received the First Market Approval for Novel Long-acting Erythropoietin, Efepoetin Alfa, from The Indonesian Food and Drug Authority (BPOM)","therapeuticArea":"Nephrology","highestDevelopmentStatus":"Approved","country":"INDONESIA","productType":"Large molecule","productStatus":"Approved","date":"October 2023","url1":"","url2":"","graph1":"Nephrology","graph2":"Approved"}]

    Find Clinical Drug Pipeline Developments & Deals by Kalbe Genexine Biologics

    Menu

    Kalbe Genexine Biologics

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Kalbe Genexine Biologics

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Indonesia
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Genexine and KGbio Received the First Market Approval for Novel Long-acting Erythropoietin, Efepoetin Alfa, from The Indonesian Food and Drug Authority (BPOM)

              Details:

              Efesa (efepoetin alfa) is a bio-better drug for CKD-induced anemia, developed based on hyFc®, Genexine's proprietary long-acting platform technology, which is investigated for the treatment of chronic kidney disease induced anemia in non-dialysis patients.

              Lead Product(s): Efepoetin Alfa

              Therapeutic Area: Nephrology Product Name: Efesa

              Highest Development Status: Approved Product Type: Large molecule

              Recipient: Genexine

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable October 23, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Kalbe Genexine Biologics

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Indonesia
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Henlius Expands Collaboration with KGbio to Develop, Commercialize and Supply Henlius' novel anti-PD-1 mAb HANSIZHUANG in MENA

              Details:

              Under the terms of the agreement, Henlius will be responsible for development and commercialisation of Hansizhuang (serplulimab injection) as a treatment for two indications including ES-SCLC, Henlius' novel anti-PD-1 mAb, in 12 MENA countries.

              Lead Product(s): Serplulimab

              Therapeutic Area: Oncology Product Name: Hansizhuang

              Highest Development Status: Approved Product Type: Large molecule

              Recipient: Shanghai Henlius Biotech

              Deal Size: $665.0 million Upfront Cash: $7.0 million

              Deal Type: Licensing Agreement September 12, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Kalbe Genexine Biologics

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Indonesia
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              KGBio and Genexine Signed Immuno-Oncology Drug License Agreement GX-17

              Details:

              Through this licensing agreement, KGBio and Genexine aim to develop a and commercialize an immuno-oncology drug GX-I7 (Efineptakin Alpha), namely long-acting interleukin-7 which uses the Genexine hyFc technology platform.

              Lead Product(s): Efineptakin alfa

              Therapeutic Area: Oncology Product Name: GX-I7

              Highest Development Status: Phase I Product Type: Large molecule

              Recipient: Genexine

              Deal Size: $1,100.0 million Upfront Cash: $27.0 million

              Deal Type: Licensing Agreement February 18, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Farmhispania Group, a leading European CDMO in HPAPI Technologies & High Potency Fermentation.
              One Pharma aims to be one of the leading generic companies in Europe.
              Post Enquiry
              POST ENQUIRY